BPC-157 (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject once daily subcutaneously. Dosing is extrapolated from preclinical models; human clinical validation remains limited.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label and refrigerate at 2 to 8 °C, protected from light. At 3.33 mg/mL, 1 unit = 0.01 mL » 33.3 mcg on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C (-4 °F) in dry, dark conditions; stable for 12+ months.
• Reconstituted: refrigerate at 2 to 8 °C (35.6 to 46.4 °F); avoid freeze-thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Supplies Needed

Plan based on an 8 to 16 week daily protocol with gradual titration.

Peptide Vials (BPC-157, 10 mg each):

• 8 weeks: ~3 vials (25.2 mg used).
• 12 weeks: ~5 vials (42 mg used).
• 16 weeks: ~6 vials (58.8 mg used).

Insulin Syringes (U-100):

• Per week: 7 syringes (1/day).
• 8 weeks: 56. 12 weeks: 84. 16 weeks: 112.

Bacteriostatic Water (10 mL bottles):

• 8 weeks (3 vials): 1 bottle. 12 weeks (5 vials): 2 bottles. 16 weeks (6 vials): 2 bottles.

Alcohol Swabs:

• Per week: 14 swabs (2/day).
• 8 weeks: 112 (2 x 100-count). 16 weeks: 224 (3 x 100-count).

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose and site rotation to maintain consistency.
• BPC-157 human data are preliminary; clinical decisions should involve qualified healthcare providers.

How This Works

BPC-157 is a synthetic peptide corresponding to a partial sequence of human gastric juice protein. Preclinical studies suggest it modulates nitric oxide pathways and growth-factor expression to promote angiogenesis and collagen deposition in damaged tissues. Animal models report accelerated healing of gut, tendon, ligament, and muscle injuries. A Phase I oral safety trial has been completed, and a small human case series reported improvements following intra-articular administration; however, large-scale controlled human efficacy data are not yet available.

Benefits & Side Effects

Observations from preclinical and early clinical literature.

• Supports tissue repair in gut, tendon, muscle, and skin injury models (animal data).
• Demonstrates anti-inflammatory and cytoprotective properties in preclinical settings.
• Phase I safety studies report good tolerability with no serious adverse events at tested doses.
• Occasional mild injection-site reactions (redness, itch) may occur with subcutaneous administration.
• Long-term human safety and efficacy remain under investigation.

Lifestyle Factors

Complementary strategies for best outcomes.

• Support recovery with adequate protein intake and micronutrient-rich foods.
• Balance activity and rest to allow tissue adaptation without overuse.
• Prioritize sleep and stress management to enhance natural healing processes.
• Consult qualified healthcare providers for injury-specific rehabilitation guidance.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Sikiric P et al. BPC-157 stable gastric pentadecapeptide: novel therapy for wound healing (Current Pharmaceutical Design).
2. Seiwerth S et al. BPC-157 and angiogenic growth factors: GI tract healing and beyond (Life Sciences).
3. Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: systematic review (HSS Journal, 2025).
4. Chang CH et al. BPC-157 promotes tendon-to-bone healing in rat rotator cuff model (Journal of Orthopaedic Research).